Like many other companies and institutions around the world, we are experiencing interference with some of our systems within the TNT network.
We are implementing remediation steps as quickly as possible. We have implemented operational contingencies to continue to complete collections from customers with scheduled stops. For customers who do not have a regular stop, collection should be arranged via our customer service centers.
Customers may experience delays in the transit of shipments, particularly inter-continental or non-EU European delivery, as we work to remediate our systems. Additionally, if customers do not have the facility for self-labeling, they may also experience delays.
We are not able to collect shipments of dangerous goods at this time.
We regret any inconvenience to our customers.
Amorphous drug substances can exhibit enhanced solubility over a crystalline form. However, the amorphous form may be unstable to recrystallisation during the shelf life of a product unless it is stabilised as an amorphous solid dispersion.
Using our formufastTM platform, we can rapidly identify the most suitable polymers at the correct concentration for further development. Prototypes are generated by solvent casting, co-melting, freeze drying or spray drying, fully characterised and their stability assessed.
Nonetheless, a crystalline form of a drug substance is usually the preferred amorphous form, as hygroscopicity, physical/chemical stability, isolation, drying, compaction and flowability may be adversely affected by a lack of crystallinity. In addition, a route to a crystalline form may be desired as a means of purification and/or structure determination of the compound.
If your API has not been observed in a crystalline state to date, our crystallisation screening service incorporates tried and tested techniques, polymer templates and hetero-nucleants. The scope will be tailored to your needs, development phase and budget.